Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)
- Conditions
- Multiple Myeloma
- Registration Number
- NCT05238311
- Lead Sponsor
- Pfizer
- Brief Summary
Provide pre-approval single-patient Expanded Access (Compassionate Use) of elranatamab for patients with relapsed/refractory multiple myeloma
- Detailed Description
In Expanded Access, treating physicians are the Sponsors
Expanded Access requests from treating physicians should be directed to www.pfizercares.com Availability will depend on location.
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie elranatamab's efficacy in relapsed/refractory multiple myeloma?
How does elranatamab compare to standard-of-care therapies like daratumumab in clinical outcomes?
Which biomarkers are associated with response prediction for elranatamab in multiple myeloma patients?
What adverse events are reported with elranatamab use and how are they managed in compassionate use settings?
Are there combination therapies involving elranatamab and other B-cell maturation antigen targeting agents in development for multiple myeloma?